Immunoreactive Molecules for NY-BR-1 Specific Cancer Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapies targeting NY-BR-1 face challenges due to cross-reactivity with closely related proteins like NY-BR-1.1, leading to potential targeting of healthy tissues and reduced efficacy in cancer treatment.

Innovation Solution

Development of immunoreactive molecules that specifically recognize and bind to NY-BR-1 without cross-reactivity to NY-BR-1.1 or its Isoform 2, utilizing unique epitope recognition and antigen binding sequences to ensure targeted therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunoreactive molecules target NY-BR-1 antigen, then cancer treatment efficacy is improved, but cross-reactivity with NY-BR-1.1 and Isoform 2 causes damage to healthy tissues

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoiddamage to healthy tissues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by engineering the immunoreactive molecule to recognize a specific local epitope region on NY-BR-1 that is structurally distinct from NY-BR-1.1 and Isoform 2. This localized epitope recognition ensures high specificity for cancer cells while sparing healthy tissues expressing the related proteins.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by modifying the binding characteristics of the immunoreactive molecule through specific amino acid sequence selection in the antigen-binding region. These parameter changes in molecular structure enable discrimination between NY-BR-1 and its closely related proteins, achieving both high efficacy and reduced cross-reactivity.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If immunoreactive molecules show high specificity for NY-BR-1, then therapeutic precision is improved, but development complexity increases due to need for unique epitope recognition

Engineering Contradiction:

Improvetherapeutic precisionVSAvoiddevelopment complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies the taking out principle by extracting and isolating the specific epitope sequence from the full NY-BR-1 protein structure. By focusing on this extracted epitope region that is unique to NY-BR-1, the development process is simplified while achieving high therapeutic precision through targeted recognition.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The immunoreactive molecules achieve high specificity for NY-BR-1, minimizing damage to healthy tissues and enhancing the therapeutic options for treating NY-BR-1 positive cancers, such as testicular and breast cancer.

Implementation Method 1

an immunoreactive molecule, wherein said immunoreactive molecule specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY-BR-1)

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS20250043020A1Immunoreactive molecules and uses thereof

Publication Date: 2025.02.06 SCHMIDT PATRICK

AI summary

The present invention relates to an immunoreactive molecule that specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY-BR-1) and, in particular, to an immunoreactive molecule, which shows no cross-reactivity to other human Ankyrin repeat domain containing proteins. The invention further relates to the use of such immunoreactive molecules in the treatment of cancer as well as in companion diagnostics methods.